News
Non-invasive test could significantly cut diagnosis time for endometriosis
The test could mean women will not have to undergo the laparoscopic surgery, currently used to diagnose the condition
A new non-invasive endometriosis test could speed up diagnosis time and enable millions to access early treatment.
Endometriosis is a condition where tissue similar to the lining of the womb grows elsewhere in the body, affecting women of all ages, including teenagers.
In the UK, it takes on average eight years from the onset of symptoms to get a diagnosis. However, a new urine test, developed by the University of Hull, could cut that to just eight days.
The test, which would be carried out at GP surgeries and clinics, could mean women will not have to undergo the laparoscopic surgery, currently used to diagnose the condition.
Lead researcher Dr Barbara Guinn, reader in biomedical sciences at the University of Hull, says the EndoTect could be crucial, as it would help identify sufferers before serious damage is done.
“We want women to be able to have this urine test and much more quickly go to the right treatment and the sooner we treat endometriosis, the less invasive it is,” she told the BBC.
“The less damage it causes and that’s better for patients, but also for the NHS.
“At the moment, endometriosis is believed to cost the UK economy £8.2bn a year, very close to the amount diabetes costs the UK economy.
“So it has a huge impact, but compared to a lot of other diseases, it’s had a tiny amount of funding. By bringing in a non-invasive test, it’s the first step in making a difference to women, treatment and outcomes.”
Guinn has been testing samples from women with endometriosis and attend specialist clinics at Castle Hill Hospital in East Yorkshire, but she needs to look at more samples to confirm her early findings.
She is now asking for healthy women aged 18 to 50 to volunteer by donating a urine sample into a sterile collection pot.
To volunteer for this study, please email Dr Barbara Guinn at b.guinn@hull.ac.uk.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur7 days agoUS startup builds wearable hormone tracker
-
Menopause3 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Menopause2 weeks agoStudy reveals gap between perimenopause expectations and experience
-
Fertility6 days agoFrance urges 29-year-olds to start families now






